How well does Truqap(Capivasertib) work?

A summary of the drug's performance in clinical studies.

Treatment Efficacy

The efficacy of TRUQAP combined with fulvestrant was established in the CAPItello-291 trial for patients with PIK3CA/AKT1/PTEN-altered tumors. The combination demonstrated a statistically significant improvement in investigator-assessed progression-free survival (PFS) compared to placebo with fulvestrant, with a median PFS of 7.3 months versus 3.1 months and a hazard ratio of 0.50. The confirmed objective response rate was also higher in the TRUQAP group.